SIRT2 and pancreatic neoplasm: By stabilizing interactions with key residues, NPD11033 not only inhibits the deacetylase activity of SIRT2 but also impairs the proliferation of pancreatic cancer cells, as evidenced by the increased acetylation of its physiological substrate, eukaryotic translation initiation factor 5A (eIF5A).